Compare IT & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IT | ARWR |
|---|---|---|
| Founded | 1979 | 2003 |
| Country | United States | United States |
| Employees | 40 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 10.2B |
| IPO Year | 2010 | 2009 |
| Metric | IT | ARWR |
|---|---|---|
| Price | $127.49 | $81.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $189.25 | $83.40 |
| AVG Volume (30 Days) | 1.2M | ★ 1.3M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 99.80 |
| EPS | ★ 3.18 | N/A |
| Revenue | ★ $2,021,441,000.00 | $16,142,321.00 |
| Revenue This Year | $3.52 | N/A |
| Revenue Next Year | $5.08 | N/A |
| P/E Ratio | $39.87 | ★ N/A |
| Revenue Growth | ★ 13.30 | N/A |
| 52 Week Low | $126.44 | $14.30 |
| 52 Week High | $409.76 | $84.55 |
| Indicator | IT | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 27.02 | 62.31 |
| Support Level | N/A | $70.05 |
| Resistance Level | $162.80 | $82.26 |
| Average True Range (ATR) | 7.87 | 4.14 |
| MACD | -3.87 | 0.60 |
| Stochastic Oscillator | 2.43 | 82.11 |
Gartner Inc delivers actionable, objective business and technology insights that drive smarter decisions and stronger performance on an organization's mission-critical priorities. It delivers its products and services globally through three reportable segments - Business and Technology Insights, Conferences and Consulting. Insights equips executives and their teams from every Majority function, geography, industry and sector with actionable, objective insights, guidance and tools. Conferences provides executives and teams across an organization the opportunity to learn, share and network. and Consulting serves senior executives technology-driven strategic initiatives leveraging the power of Gartner's actionable, objective insight. The Majority revenue is derived from the Insights segment.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.